S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Fulgent Genetics Stock Forecast, Price & News

+8.18 (+9.15%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
961,635 shs
Average Volume
1.09 million shs
Market Capitalization
$2.91 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive FLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulgent Genetics and its competitors with MarketBeat's FREE daily newsletter.

Fulgent Genetics logo

About Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.


See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$421.71 million
Cash Flow
$9.75 per share
Book Value
$35.01 per share


Net Income
$214.31 million
Pretax Margin




Free Float
Market Cap
$2.91 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.04 out of 5 stars

Medical Sector

552nd out of 1,391 stocks

Medical Laboratories Industry

14th out of 30 stocks

Analyst Opinion: 2.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions

Is Fulgent Genetics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics
or view top-rated stocks.

How has Fulgent Genetics' stock price been impacted by COVID-19 (Coronavirus)?

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, FLGT shares have increased by 870.0% and is now trading at $97.58.
View which stocks have been most impacted by COVID-19

When is Fulgent Genetics' next earnings date?

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Fulgent Genetics

How were Fulgent Genetics' earnings last quarter?

Fulgent Genetics, Inc. (NASDAQ:FLGT) issued its earnings results on Monday, August, 9th. The company reported $2.47 earnings per share for the quarter, missing the consensus estimate of $2.54 by $0.07. The business had revenue of $153.60 million for the quarter, compared to analysts' expectations of $197.34 million. Fulgent Genetics had a trailing twelve-month return on equity of 67.68% and a net margin of 54.96%. Fulgent Genetics's revenue was up 789.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.19 earnings per share.
View Fulgent Genetics' earnings history

What guidance has Fulgent Genetics issued on next quarter's earnings?

Fulgent Genetics updated its FY 2021 earnings guidance on Tuesday, November, 23rd. The company provided earnings per share (EPS) guidance of $16.000-$16.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.240. The company issued revenue guidance of $930 million-$930 million, compared to the consensus revenue estimate of $948.20 million.

What price target have analysts set for FLGT?

3 Wall Street analysts have issued 1-year target prices for Fulgent Genetics' stock. Their forecasts range from $65.00 to $140.00. On average, they anticipate Fulgent Genetics' share price to reach $111.67 in the next year. This suggests a possible upside of 14.4% from the stock's current price.
View analysts' price targets for Fulgent Genetics
or view top-rated stocks among Wall Street analysts.

Who are Fulgent Genetics' key executives?

Fulgent Genetics' management team includes the following people:
  • Ming Hsieh, Chairman, President & Chief Executive Officer
  • James Xie, Chief Operating Officer
  • Paul H. Kim, Chief Financial Officer
  • Harry Gao, Chief Scientific Officer & Laboratory Director
  • Lawrence M. Weiss, Chief Medical Officer

What other stocks do shareholders of Fulgent Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

When did Fulgent Genetics IPO?

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

What is Fulgent Genetics' stock symbol?

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Who are Fulgent Genetics' major shareholders?

Fulgent Genetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.42%), Geode Capital Management LLC (1.22%), Invesco Ltd. (0.94%), Point72 Asset Management L.P. (0.75%), Bank of New York Mellon Corp (0.69%) and Nepsis Inc. (0.66%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends for Fulgent Genetics

Which institutional investors are selling Fulgent Genetics stock?

FLGT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Sculptor Capital LP, Skandinaviska Enskilda Banken AB publ , Dimensional Fund Advisors LP, Jane Street Group LLC, Citadel Advisors LLC, Deutsche Bank AG, and Capital Fund Management S.A.. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics
or view top insider-selling stocks.

Which institutional investors are buying Fulgent Genetics stock?

FLGT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., PEAK6 Investments LLC, Marshall Wace LLP, American Century Companies Inc., Jupiter Asset Management Ltd., Man Group plc, and Geode Capital Management LLC.
View insider buying and selling activity for Fulgent Genetics
or or view top insider-buying stocks.

How do I buy shares of Fulgent Genetics?

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulgent Genetics' stock price today?

One share of FLGT stock can currently be purchased for approximately $97.58.

How much money does Fulgent Genetics make?

Fulgent Genetics has a market capitalization of $2.91 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $19.20 on an earnings per share basis.

How many employees does Fulgent Genetics have?

Fulgent Genetics employs 429 workers across the globe.

What is Fulgent Genetics' official website?

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Where are Fulgent Genetics' headquarters?

Fulgent Genetics is headquartered at 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780.

How can I contact Fulgent Genetics?

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at (626) 350-0537, via email at [email protected], or via fax at 626-454-1667.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.